Angiogenesis-related biomarkers (sFlt-1/PLGF) in the prediction and diagnosis of placental dysfunction: An approach for clinical integration

International Journal of Molecular Sciences

Volumn 16, Issue 8, 2015, Pages 19009-19026

  Herraiz, Ignacio ^a   Simón, Elisa ^a   Gómez Arriaga, Paula Isabel ^a   Martínez Moratalla, José Manuel ^a   García Burguillo, Antonio ^a   López Jiménez, Elena Ana ^a   Galindo, Alberto ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Angiogenesis; Intrauterine growth restriction; Placental abruption; Placental insufficiency; PlGF; Preeclampsia; SFlt 1

Indexed keywords

BIOLOGICAL MARKER; PLACENTAL GROWTH FACTOR; FLT1 PROTEIN, HUMAN; PGF PROTEIN, HUMAN; PLACENTA PROTEIN; VASCULOTROPIN RECEPTOR 1;

ANGIOGENESIS; CHROMOSOME ABERRATION; CLINICAL PRACTICE; CONGENITAL INFECTION; HUMAN; INTRAUTERINE GROWTH RETARDATION; KNOWLEDGE; PERINATAL MORBIDITY; PERINATAL MORTALITY; PLACENTA DISORDER; PLACENTA INSUFFICIENCY; PLACENTA PERFUSION; PREECLAMPSIA; PREMATURITY; PRENATAL CARE; REVIEW; RISK FACTOR; RISK REDUCTION; SOLUTIO PLACENTAE; ABRUPTIO PLACENTAE; FEMALE; FETAL GROWTH RETARDATION; NEOVASCULARIZATION, PATHOLOGIC; PATHOPHYSIOLOGY; PLACENTA; PRE-ECLAMPSIA; PREGNANCY; PROGNOSIS; VASCULARIZATION;

ABRUPTIO PLACENTAE; BIOMARKERS; FEMALE; FETAL GROWTH RETARDATION; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PLACENTA; PLACENTA GROWTH FACTOR; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY PROTEINS; PROGNOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84939216800     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms160819009     Document Type: Review

References (65)

1. Friedman, A.M.; Cleary, K.L. Prediction and prevention of ischemic placental disease. Semin. Perinatol. 2014, 38, 177-182.
2. Hagmann, H.; Thadhani, R.; Benzing, T.; Karumanchi, S.A.; Stepan, H. The promise of angiogenic markers for the early diagnosis and prediction of preeclampsia. Clin. Chem. 2012, 58, 837-845.
3. Menzies, J.; Magee, L.A.; Macnab, Y.C.; Ansermino, J.M.; Li, J.; Douglas, M.J.; Gruslin, A.; Kyle, P.; Lee, S.K.; Moore, M.P. et al. Current CHS and NHBPEP criteria for severe preeclampsia do not uniformly predict adverse maternal or perinatal outcomes. Hypertens. Pregnancy 2007, 26, 447-462.
4. Figueras, F.; Gratacos, E. Update on the diagnosis and classification of fetal growth restriction and proposal of a stage-based management protocol. FetalDiagn. Ther. 2014, 36, 86-98.
5. Hall, D.R. Abruptio placentae and disseminated intravascular coagulopathy. Semin. Perinatol. 2009, 33, 189-195.
6. Burton, G.J.; Woods, A.W.; Jauniaux, E.; Kingdom, J.C. Rheological and physiological consequences of conversion of the maternal spiral arteries for uteroplacental blood flow during human pregnancy. Placenta 2009, 30, 473-482.
7. Roberts, J.M. Pathophysiology of ischemic placental disease. Semin. Perinatol. 2014, 38, 139-145.
8. Maynard, S.E.; Min, J.Y.; Merchan, J.; Lim, K.H.; Li, J., Mondal, S., Libermann, T. A., Morgan, J. P., Sellke, F. W., Stillman, I. E. et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Investig. 2003, 111, 649-658.
9. Shibuya, M. Vascular endotelial growth factor and its receptor system: Physiological functions in angiogenesis and pathological roles in various diseases. J. Biochem. 2013, 153, 13-19.
10. Sircar, M.; Thadhani, R.; Karumanchi, S.A. Pathogenesis of preeclampsia. Curr. Opin. Nephrol. Hypertens. 2015, 24, 131-138.
11. Weiler, J.; Tong, S.; Palmer, K.R. Is fetal growth restriction associated with a more severe maternal phenotype in the setting of early onset pre-eclampsia? A retrospective study. PLoS ONE 2011, 6, e26937.
12. Signore, C.; Mills, J.L.; Qian, C.; Yu, K.; Lam, C.; Epstein, F.H.; Karumanchi, S.A.; Levine, R.J. Circulating angiogenic factors and placental abruption. Obstet. Gynecol. 2006, 108, 338-344.
13. Gomez-Arriaga, P.I.; Herraiz, I.; Lopez-Jimenez, E.A.; Escribano, D.; Denk, B.; Galindo, A. Uterine artery Doppler and sFlt-1/PlGF ratio: Prognostic value in early-onset pre-eclampsia. Ultrasound Obstet. Gynecol. 2014, 43, 525-532.
14. Chaiworapongsa, T.; Romero, R.; Korzeniewski, S.J.; Cortez, J.M.; Pappas, A.; Tarca, A.L.; Chaemsaithong, P.; Dong, Z.; Yeo, L.; Hassan, S.S. Plasma concentrations of angiogenic/ anti-angiogenic factors have prognostic value in women presenting with suspected preeclampsia to the obstetrical triage area: A prospective study. J. Matern. Fetal Neonatal Med. 2014, 27, 132-144.
15. Roberts, J.M.; Catov, J.M. Preeclampsia more than 1 disease or is it? Hypertension 2008, 51, 989-990.
16. Herraiz, I.; Dröge, L.A.; Gómez-Montes, E.; Henrich, W.; Galindo, A.; Verlohren, S. Characterization of the soluble fms-like tyrosine kinase-1 to placental growth factor ratio in pregnancies complicated by Fetal Growth Restriction. Obstet. Gynecol. 2014, 124, 265-273.
17. Rana, S.; Schnettler, W.T.; Powe, C.; Wenger, J.; Salahuddin, S.; Cerdeira, A.S.; Verlohren, S.; Perschel, F.H.; Arany, Z.; Lim, K. H. et al. Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. Hypertens. Pregnancy 2013, 32, 189-201.
18. Espinoza, J. Abnormal fetal-maternal interactions: An evolutionary value? Obstet. Gynecol. 2012, 120, 370-374.
19. Roberts, J.M.; Hubel, C.A. The two stage model of preeclampsia: Variations on the theme. Placenta 2009, 30, S32-S37.
20. Wright, D.; Syngelaki, A.; Akolekar, R.; Poon, L.C.; Nicolaides, K.H. Competing risks model in screening for preeclampsia by maternal characteristics and medical history. Am. J. Obstet. Gynecol. 2015, 213, 62.e1-62.e10.
21. Redman, C.W.; Sargent, I.L.; Staff, A.C. IFPA Senior Award Lecture: Making sense of pre-eclampsia—Two placental causes of preeclampsia? Placenta 2014, 35 (Suppl. 102), 20-25.
22. Espinoza, J. Uteroplacental ischemia in early- and late-onset pre-eclampsia: A role for the fetus? Ultrasound Obstet. Gynecol. 2012, 40, 373-382.
23. Levine, R.J.; Maynard, S.E.; Qian, C.; Lim, K.H.; England, L.J.; Yu, K.F.; Schisterman, E.F.; Thadhani, R.; Sachs, B.P.; Epstein, F.H. et al. Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 2004, 350, 672-683.
24. Verlohren, S.; Herraiz, I.; Lapaire, O.; Schlembach, D.; Zeisler, H.; Calda, P.; Sabria, J.; Markfeld-Erol, F.; Galindo, A.; Schoofs, K. et al. New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension 2014, 63, 346-352.
25. Verlohren, S.; Galindo, A.; Schlembach, D.; Zeisler, H.; Herraiz, I.; Moertl, M.G.; Pape, J.; Dudenhausen, J.W.; Denk, B.; Stepan, H. An automated method for the determination of the sFlt-1/ PIGF ratio in the assessment of preeclampsia. Am. J. Obstet. Gynecol. 2010, 202, 161. e1-161.e11.
26. Stepan, H.; Herraiz, I.; Schlembach, D.; Verlohren, S.; Brennecke, S.; Chantraine, F.; Klein, E.; Lapaire, O.; Llurba, E.; Ramoni, A.; et al. Implementation of the sFlt-1/PlGF ratio for prediction and diagnosis of pre-eclampsia in singleton pregnancy: Implications for clinical practice. Ultrasound Obstet. Gynecol. 2015, 45, 241-246.
27. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. A randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. Lancet 1994, 343, 619-629.
28. Caritis, S.; Sibai, B.; Hauth, J.; Lindheimer, M.D.; Klebanoff, M.; Thom, E.; van Dorsten, P.; Landon, M.; Paul, R.; Miodovnik, M. et al. Low-dose aspirin to prevent preeclampsia in women at high risk. N. Engl. J. Med. 1998, 335, 701-705.
29. Yu, C.K.; Papageorghiou, A.T.; Parra, M.; Palma Dias, R.; Nicolaides, K.H. Randomized controlled trial using low-dose aspirin in the prevention of pre-eclampsia in women with abnormal uterine artery Doppler at 23 weeks' gestation. Ultrasound Obstet. Gynecol. 2003, 22, 233-239.
30. National Collaborating Centre for Women's and Children's Health. Hypertension in Pregnancy: The Management of Hypertensive Disorders during Pregnancy. Clinical Guideline; RCOG Press: London, UK, August 2010.
31. Verlohren, S.; Stepan, H.; Dechend, R. Angiogenic growth factors in the diagnosis and prediction of pre-eclampsia. Clin. Sci. 2012, 122, 43-52.
32. Thadhani, R.; Mutter, W.P.; Wolf, M.; Levine, R.J.; Taylor, R.N.; Sukhatme, V.P.; Ecker, J.; Karumanchi, S.A. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J. Clin. Endocrinol. Metab. 2004, 89, 770-775.
33. Baumann, M.U.; Bersinger, N.A.; Mohaupt, M.G.; Raio, L.; Gerber, S.; Surbek, D.V. First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia. Am. J. Obstet. Gynecol. 2008, 199, 266.e1-266.
34. Akolekar, R.; Syngelaki, A.; Sarquis, R.; Zvanca, M.; Nicolaides, K.H. Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks. Prenat. Diagn. 2011, 31, 66-74.
35. Crovetto, F.; Crispi, F.; Scazzocchio, E.; Mercade, I.; Meler, E.; Figueras, F.; Gratacos, E. First-trimester screening for early and late small-for-gestational-age neonates using maternal serum biochemistry, blood pressure and uterine artery Doppler. Ultrasound Obstet. Gynecol. 2014, 43, 34-40.
36. Oliveira, N.; Magder, L.S.; Blitzer, M.G.; Baschat, A.A. First-trimester prediction of pre-eclampsia: External validity of algorithms in a prospectively enrolled cohort. Ultrasound Obstet. Gynecol. 2014, 44, 279-285.
37. Shmueli, A.; Meiri, H.; Gonen, R. Economic assessment of screening for pre-eclampsia. Prenat. Diagn. 2012, 32, 29-38.
38. Abou, E. l.; Hassan, M.; Diamandis, E. P.; Karumanchi, S. A.; Shennan, A. H.; Taylor, R. N. Preeclampsia: An old disease with new tools for better diagnosis and risk management. Clin. Chem. 2015, 61, 694-698.
39. Gómez-Arriaga, P.I.; Herraiz, I.; López-Jiménez, E.A.; Gómez-Montes, E.; Denk, B.; Galindo, A. Uterine artery Doppler and sFlt-1/PlGF ratio: Usefulness in diagnosis of pre-eclampsia. Ultrasound Obstet. Gynecol. 2013, 41, 530-537.
40. Sagol, S.; Ozkinay, E.; Oztekin, K.; Ozdemir, N. The comparison of uterine artery Doppler velocimetry with the histopathology of the placental bed. Aust. N. Zeal. J. Obstet. Gnaecol. 1999, 39, 324-329.
41. Sciscione, A.C.; Hayes, E.J. Uterine artery Doppler flow studies in obstetric practice. Am. J. Obstet. Gynecol. 2009, 201, 121-126.
42. Martin, A.M.; Bindra, R.; Curcio, P.; Cicero, S.; Nicolaides, K.H. Screening for pre-eclampsia and fetal growth restriction by uterine artery Doppler at 11-14 weeks of gestation. Ultrasound Obstet. Gynecol. 2001, 18, 583-586.
43. Cnossen, J.S.; Morris, R.K.; ter Riet, G.; Mol, B.W.; van der Post, J.A.; Coomarasamy, A.; Zwinderman, A.H.; Robson, S.C.; Bindels, P.J.; Kleijnen, J.; et al. Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: A aystematic review and bivariable meta-analysis. CMAJ 2008, 178, 701-711.
44. Velauthar, L.; Plana, M.N.; Kalidindi, M.; Zamora, J.; Thilaganathan, B.; Illanes, S.E.; Khan, K.S.; Aquilina, J.; Thangaratinam, S. First-trimester uterine artery Doppler and adverse pregnancy outcome: A meta-analysis involving 55974 women. Ultrasound Obstet. Gynecol. 2014, 43, 500-507.
45. Ghi, T.; Contro, E.; Youssef, A.; Giorgetta, F.; Farina, A.; Pilu, G.; Pelusi, G. Persistence of increased uterine artery resistance in the third trimester and pregnancy outcome. Ultrasound Obstet. Gynecol. 2010, 36, 577-581.
46. Stepan, H.; Unversucht, A.; Wessel, N.; Faber, R. Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension 2007, 49, 818-824.
47. Crispi, F.; Llurba, E.; Domínguez, C.; Martín-Gallán, P.; Cabero, L.; Gratacós, E. Predictive value of angiogenic factors and uterine artery Doppler for early- versus late-onset pre-eclampsia and intrauterine growth restriction. Ultrasound Obstet. Gynecol. 2008, 31, 303-309.
48. Kusanovic, J.P.; Romero, R.; Chaiworapongsa, T.; Erez, O.; Mittal, P.; Vaisbuch, E.; Mazaki-Tovi, S.; Gotsch, F.; Edwin, S.S.; Gomez, R. et al. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J. Matern. Fetal Neonatal Med. 2009, 22, 1021-1038.
49. Stubert, J.; Ullmann, S.; Bolz, M.; Külz, T.; Dieterich, M.; Richter, D.-U.; Reimer, T. Prediction of preeclampsia and induced delivery at <34 weeks gestation by sFLT-1 and PlGF in patients with abnormal midtrimester uterine Doppler velocimetry: A prospective cohort analysis. BMC Pregnancy Childbirth 2014, 14, 292, doi:10.1186/1471-2393-14-292.
50. Lai, J.; Garcia-Tizon Larroca, S.; Peeva, G.; Poon, L.C.; Wright, D.; Nicolaides, K.H. Competing risks model in screening for preeclampsia by serum placental growth factor and soluble fms-like tyrosine kinase-1 at 30-33 weeks' gestation. Fetal Diagn. Ther. 2014, 35, 240-248.
51. Lisonkova, S.; Sabr, Y.; Mayer, C.; Young, C.; Skoll, A.; Joseph, K.S. Maternal morbidity associated with early-onset and late-onset preeclampsia. Obstet. Gynecol. 2014, 124, 771-781.
52. Bombrys, A.E.; Barton, J.R.; Nowacki, E.A.; Habli, M.; Pinder, L.; How, H.; Sibai, B.M. Expectant management of severe preeclampsia at less than 27 weeks' gestation: Maternal and perinatal outcomes according to gestational age by weeks at onset of expectant management. Am. J. Obstet. Gynecol. 2008, 199, 247.e1-e6.
53. Belghiti, J.; Kayem, G.; Tsatsaris, V.; Goffinet, F.; Sibai, B.M.; Haddad, B. Benefits and risks of expectant management of severe preeclampsia at less than 26 weeks gestation: The impact of gestational age and severe fetal growth restriction. Am. J. Obstet. Gynecol. 2011, 205, 465.e1-465.e6.
54. Manktelow, B.N.; Seaton, S.E.; Field, D.J.; Draper, E.S. Population-based estimates of in-unit survival for very preterm infants. Pediatrics 2013, 131, 425-432.
55. Menzies, J.; Magee, L.A.; Li, J.; MacNab, Y.C.; Yin, R.; Stuart, H.; Baraty, B.; Lam, E.; Hamilton, T.; Lee, S.K.; et al. Instituting surveillance guidelines and adverse outcomes in preeclampsia. Obstet. Gynecol. 2007, 110, 121-127.
56. Zeisler, H.; Llurba, E.; Chantraine, F.; Vatish, M.; Staff, A.; Sennström, M.; Olovsson, M.; Brennecke, S.; Stepan, H.; Allegranza, D. et al. Prediction of short-term outcome in pregnant women with suspected preeclampsia: The PROGNOSIS study. COGI 2014, Paris. Abstract P79. Available online: http://www.congressmed.com/cogi/images/pdf/COGIParisAbstractBook.pdf. (accessed on 11 August 2015).
57. Rana, S.; Karumanchi, S.A.; Lindheimer, M.D. Angiogenic factors in diagnosis, management, and research in preeclampsia. Hypertension 2014, 63, 198-202.
58. Schnettler, W.; Dukhovny, D.; Wenger, J.; Salahuddin, S.; Ralston, S.; Rana, S. Cost and resource implications with serum angiogenic factor estimation in the triage of pre-eclampsia. BJOG 2013, 120, 1224-1232.
59. Verlohren, S.; Herraiz, I.; Lapaire, O.; Schlembach, D.; Moertl, M.; Zeisler, H.; Calda, P.; Holzgreve, W.; Galindo, A.; Engels, T. et al. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am. J. Obstet. Gynecol. 2012, 206, 58.e1-58.e8.
60. Rana, S.; Powe, C.E.; Salahuddin, S.; Verlohren, S.; Perschel, F.H.; Levine, R.J.; Lim, K.H.; Wenger, J.B.; Thadhani, R.; Karumanchi, S.A. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012, 125, 911-919.
61. Schaarschmidt, W.; Rana, S.; Stepan, H. The course of angiogenic factors in early- vs. late-onset preeclampsia and HELLP síndrome. J. Perinat. Med. 2013, 41, 511-516.
62. Dröge, L.; Herraiz, I.; Zeisler, H.; Schlembach, D.; Stepan, H.; Küssel, L.; Henrich, W.; Galindo, A.; Verlohren, S. Maternal serum sFlt-1/PlGF ratio in twin pregnancies with and without pre-eclampsia in comparison with singleton pregnancies. Ultrasound Obstet. Gynecol. 2015, 45, 286-293.
63. Rana, S.; Venkatesha, S.; DePaepe, M.; Chien, E.K.; Paglia, M.; Karumanchi, S.A. Cytomegalovirus-induced mirror syndrome associated with elevated levels of circulating antiangiogenic factors. Obstet. Gynecol. 2007, 109, 549-552.
64. Bdolah, Y.; Palomaki, G.E.; Yaron, Y.; Bdolah-Abram, T.; Goldman, M.; Levine, R.J.; Sachs, B.P.; Haddow, J.E.; Karumanchi, S.A. Circulating angiogenic proteins in trisomy 13. Am. J. Obstet. Gynecol. 2006, 194, 239-245.
65. Llurba, E.; Sánchez, O.; Ferrer, Q.; Nicolaides, K.H.; Ruíz, A.; Domínguez, C.; Sánchez-de-Toledo, J.; García-García, B.; Soro, G.; Arévalo, S.; Goya, M. et al. Maternal and foetal angiogenic imbalance in congenital heart defects. Eur. Heart J. 2014, 35, 701-707.